Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fexaflu
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Fexaflu is an oral antihistamine marketed by Medimet Pharmaceuticals in Bangladesh. It contains fexofenadine hydrochloride, a second-generation H1-receptor antagonist. As a small molecule, fexofenadine works by selectively blocking peripheral H1 receptors, preventing histamine-mediated allergic responses without significant sedative effects due to its limited ability to cross the blood-brain barrier. It is indicated for the symptomatic relief of seasonal allergic rhinitis and chronic idiopathic urticaria. Fexaflu is available as a generic film-coated tablet formulation.
- Brand names
- FexafluFexaflu 120Fexaflu120Fexaflu-120
- Other names
- fexofenadine hydrochloridefexofenadine
02
Targets
HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on Fexaflu.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fexaflu.